close 74% de inversores minoristas pierde dinero cuando opera con CFDs en este proveedor. Las inversiones conllevan riesgos y no son adecuadas para todos los inversores. Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento. 74% de inversores minoristas pierde dinero cuando opera con CFDs en este proveedor. Debes considerar si comprendes cómo funcionan los CFDs y si puedes permitirte asumir el alto riesgo de perder tu dinero.
BuscarBuscar
Change languageEspañol
Dashboard

LLY

1,027.65

-1.77%↓

JNJ

244.73

-0.4%↓

ABBV

226.81

-0.56%↓

NVS

167.17

+0.34%↑

MRK

122.45

-1.5%↓

LLY

1,027.65

-1.77%↓

JNJ

244.73

-0.4%↓

ABBV

226.81

-0.56%↓

NVS

167.17

+0.34%↑

MRK

122.45

-1.5%↓

LLY

1,027.65

-1.77%↓

JNJ

244.73

-0.4%↓

ABBV

226.81

-0.56%↓

NVS

167.17

+0.34%↑

MRK

122.45

-1.5%↓

LLY

1,027.65

-1.77%↓

JNJ

244.73

-0.4%↓

ABBV

226.81

-0.56%↓

NVS

167.17

+0.34%↑

MRK

122.45

-1.5%↓

LLY

1,027.65

-1.77%↓

JNJ

244.73

-0.4%↓

ABBV

226.81

-0.56%↓

NVS

167.17

+0.34%↑

MRK

122.45

-1.5%↓

Inicio・Lista de Acciones・Nektar Therapeutics
Search

Nektar Therapeutics

Abierto

70.02 2.01

Compra Fuerte

Precios actualizados 25 feb 2026, 19:21 UTC

ComprarVender

Resumen

Variación precio

24h

Actual

Mínimo

67.91

Máximo

71.24

Métricas clave

By Trading Economics

Ingresos

6.1M

-36M

Ventas

615K

12M

BPA

-1.87

Margen de beneficios

-301.289

Empleados

61

EBITDA

6.9M

-29M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+89.8% upside

Dividendos

By Dow Jones

Próximas Ganancias

11 mar 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

920M

2.1B

Apertura anterior

68.01

Cierre anterior

70.02

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

0.5949 / 0.7406 Soporte y Resistencia

Nektar Therapeutics Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

24 feb 2026, 23:07 UTC

Ganancias

Woolworths 1st Half Profit Hit By Worker Pay Dispute, Still Boosts Dividend

DJ

Leer

24 feb 2026, 23:01 UTC

Ganancias

Fortescue 1st Half Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

DJ

Leer

24 feb 2026, 22:59 UTC

Ganancias

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability -- Update

DJ

Leer

24 feb 2026, 22:42 UTC

Ganancias

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability

DJ

Leer

24 feb 2026, 22:24 UTC

Adquisiciones, fusiones, absorciones

Warner Bros. Discovery Board Says Paramount Skydance's New Proposal Could Top Netflix Agreement -- Update

DJ

Leer

24 feb 2026, 23:46 UTC

Charlas de Mercado

Gold Edges Higher Amid Possible Position Adjustments -- Market Talk

DJ

Leer

24 feb 2026, 23:36 UTC

Charlas de Mercado

Nikkei May Rise, Tracking Wall Street's Rebound -- Market Talk

DJ

Leer

24 feb 2026, 23:30 UTC

Charlas de Mercado

Fortescue's Copper Bet Is Long Term, While Iron Ore Remains Near-Term Driver -- Market Talk

DJ

Leer

24 feb 2026, 23:20 UTC

Charlas de Mercado

Fortescue Dividend Beat Overshadows Profit Miss -- Market Talk

DJ

Leer

24 feb 2026, 23:20 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

DJ

Leer

24 feb 2026, 23:16 UTC

Ganancias

Oversea-Chinese Banking Corp.'s CEO: "Looking Ahead, We Remain Cautious Yet Positive">O39.SG

DJ

Leer

24 feb 2026, 23:13 UTC

Ganancias

Oversea-Chinese Banking Corp. FY25 Non-Interest Income S$5.46B Vs. S$4.72B >O39.SG

DJ

Leer

24 feb 2026, 23:12 UTC

Ganancias

Oversea-Chinese Banking Corp.: FY25 Net Interest Income S$9.15B Vs. S$9.76B>O39.SG

DJ

Leer

24 feb 2026, 23:10 UTC

Ganancias

Oversea-Chinese Banking Corp. FY25 NPL Ratio 0.9%, Unchanged on Year>O39.SG

DJ

Leer

24 feb 2026, 23:10 UTC

Ganancias

Oversea-Chinese Banking Corp. FY25 Net Interest Margin 1.91%, Down 29bps on Year>O39.SG

DJ

Leer

24 feb 2026, 23:08 UTC

Ganancias

Oversea-Chinese Banking Corp. FY25 Net S$7.42B Vs. Net S$7.59B >O39.SG

DJ

Leer

24 feb 2026, 23:07 UTC

Ganancias

Oversea-Chinese Banking Corp. FY25 Total Income S$14.61B Vs. S$14.47B>O39.SG

DJ

Leer

24 feb 2026, 22:52 UTC

Ganancias

Woolworths 1H Profit Hit By Worker Pay Dispute, Still Boosts Dividend

DJ

Leer

24 feb 2026, 22:46 UTC

Ganancias

Fortescue 1H Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

DJ

Leer

24 feb 2026, 22:31 UTC

Adquisiciones, fusiones, absorciones

Warner Receives New Bid From Paramount -- 3rd Update

DJ

Leer

24 feb 2026, 22:29 UTC

Ganancias

Woolworths: FY Ebit Growth for Australian Food Expected at Upper End of Mid-to-High Single Digit Range Provided in August

DJ

Leer

24 feb 2026, 22:28 UTC

Ganancias

Woolworths: Australian Food Current Growth Rates Reflect Some Benefit from Cycling of Industrial Action Impacts

DJ

Leer

24 feb 2026, 22:27 UTC

Ganancias

Woolworths: Australian Food Sales +7.2% Excluding Tobacco in 2H First Seven Weeks

DJ

Leer

24 feb 2026, 22:27 UTC

Ganancias

Woolworths: Australian Food Sales +5.8% in 2H First Seven Weeks

DJ

Leer

24 feb 2026, 22:25 UTC

Ganancias

Woolworths: Customers Continue to be Value-Focused, Shopping Multiple Retailers in Highly Competitive Environment

DJ

Leer

24 feb 2026, 22:24 UTC

Ganancias

Woolworths: Trading in 3Q to Date Has Been Strong in Australian Food

DJ

Leer

24 feb 2026, 22:23 UTC

Ganancias

Woolworths 1H Group Sales A$37.1 Bln, Up 3.4%

DJ

Leer

24 feb 2026, 22:22 UTC

Ganancias

Woolworths Interim Dividend 45 Australian Cents/Share

DJ

Leer

24 feb 2026, 22:22 UTC

Ganancias

Woolworths 1H Profit Before Significant Items A$859 Mln, Up 16.4%

DJ

Leer

24 feb 2026, 22:21 UTC

Ganancias

Woolworths 1H Statutory Net Profit A$374 Mln, Down 49.4%

DJ

Leer

Comparación entre iguales

Cambio de precio

Nektar Therapeutics previsión

Precio Objetivo

By TipRanks

89.8% repunte

Estimación a 12 Meses

Media 129.86 USD  89.8%

Máximo 165 USD

Mínimo 102 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Nektar Therapeutics Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

8 ratings

8

Comprar

0

Mantener

0

Vender

De acuerdo con 8 analistas que ofrecen calificaciones bursátiles a para Nektar Therapeutics Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

0.5949 / 0.7406Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Medio plazo

Strong Bearish Evidence

All events are bearish.

Largo Plazo

Bearish Evidence

All events are bearish.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Otras acciones del sector

LLY

Eli Lilly and Co.

1,027.65

↓-1.77%

JNJ

Johnson and Johnson

244.73

↓-0.4%

ABBV

AbbVie Inc

226.81

↓-0.56%

NVS

Novartis AG

167.17

↑ +0.34%

MRK

Merck & Co Inc.

122.45

↓-1.5%
help-icon Live chat